SynAct Pharma AB
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SYNACT.ST research report →
Companywww.synactpharma.com
SynAct Pharma AB, through its subsidiary, SynAct Pharma ApS, develops medicines for acute deterioration in inflammatory diseases. The company is developing AP1189, a drug candidate for the treatment of rheumatoid arthritis and idiopathic membranous glomerulonephritis. It has a partnership with the University Of Örebro to study the reduction of inflammation in vascular disease.
- CEO
- Jeppe Ovli Ovlesen
- IPO
- 2016
- Employees
- 6
- HQ
- Lund, SE
Price Chart
Valuation
- Market Cap
- $775.42M
- P/E
- -7.00
- P/S
- 0.00
- P/B
- 4.55
- EV/EBITDA
- -6.21
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -59.69%
- ROIC
- -54.64%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-110,826,000 · -34.50%
- EPS
- $-2.17 · -4.33%
- Op Income
- $-117,150,000
- FCF YoY
- -9.12%
Performance & Tape
- 52W High
- $25.30
- 52W Low
- $13.40
- 50D MA
- $16.91
- 200D MA
- $19.89
- Beta
- 0.88
- Avg Volume
- 234.49K
Get TickerSpark's AI analysis on SYNACT.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our SYNACT.ST Coverage
We haven't published any research on SYNACT.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SYNACT.ST Report →